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The transcription factor Nrf2 exerts protective effects in
numerous experimental models of acute kidney injury, and is
a promising therapeutic target in chronic kidney disease. To
provide a detailed insight into the regulatory roles of Nrf2 in
the kidney, we performed integrated transcriptomic and
proteomic analyses of kidney tissue from wild-type and Nrf2
knockout mice treated with the Nrf2 inducer methyl-2-cyano-
3,12-dioxooleano-1,9-dien-28-oate (CDDO-Me, also known as
bardoxolone methyl). After 24 h, analyses identified 2561
transcripts and 240 proteins that were differentially
expressed in the kidneys of Nrf2 knockout mice, compared
with those of wild-type counterparts, and 3122 transcripts
and 68 proteins that were differentially expressed in wild-
type mice treated with CDDO-Me, compared with those of
vehicle control. In the light of their sensitivity to genetic and
pharmacological modulation of renal Nrf2 activity, genes/
proteins that regulate xenobiotic disposition, redox balance,
the intra/extracellular transport of small molecules, and the
supply of NADPH and other cellular fuels were found to be
positively regulated by Nrf2 in the kidney. This was verified
by qPCR, immunoblotting, pathway analysis, and
immunohistochemistry. In addition, the levels of NADPH
and glutathione were found to be significantly decreased
in the kidneys of Nrf2 knockout mice. Thus, Nrf2 regulates
genes that coordinate homeostatic processes in the
kidney, highlighting its potential as a novel therapeutic
target.
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Acute kidney injury is a significant clinical problem, with
more than 7% of patients developing some form of acute
kidney injury following admission to hospital.1 Furthermore,
as a result of the renal vasculature being exposed to ~ 25% of
resting cardiac output,2 and given its role in the urinary
excretion of conjugated reactive metabolites, the kidney often
encounters relatively high levels of xenobiotics and their
metabolites, of which a number are known to suppress renal
function. A key mechanism underlying the nephrotoxicity
of many xenobiotics (examples include cisplatin,3 ferric
nitrilotriacetate,4 and streptozotocin5) is their ability to
induce the generation of reactive oxygen species (ROS) and
consequent oxidative stress in specific regions of the kidney.
The transcription factor Nrf2 is widely regarded as the
master regulator of defence against the deleterious effects of
oxidative stress in mammalian cells.6 Under normal condi-
tions, the level and activity of Nrf2 is restricted via its
association with the cytosolic protein Keap1, which targets the
transcription factor for ubiquitination and proteasomal
degradation.6 In the presence of reactive oxygen species and
other potentially harmful stimuli, Nrf2 evades Keap1-
mediated repression and accumulates in the nucleus, where
it binds to antioxidant response elements (AREs) located
in the promoter regions of cytoprotective genes, elevating
expression of their products which serve to purge the toxic
insult and minimize its damaging effects.6 As a result, there is
considerable interest in targeting Nrf2 for therapeutic benefit,
particularly in disease contexts in which reactive oxygen
species play an important role.7 Indeed, the triterpenoid Nrf2
inducer methyl-2-cyano-3,12-dioxooleano-1,9-dien-28-oate
(CDDO-Me) (also known as bardoxolone methyl) had until
recently shown promise as a novel therapy for chronic kidney
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disease (CKD),8 when a phase III clinical trial was halted
due to adverse cardiovascular events that are thought to
be associated with an Nrf2-independent perturbation of
endothelin signaling.9,10 Recently, two new phase II trials of
CDDO-Me (in CKD—NCT02316821 and pulmonary arterial
hypertension—NCT02036970) were initiated with stricter
exclusion criteria for patients with a history of cardiovascular
disease.
We previously provided insights into the molecular
mechanisms by which Nrf2 protects against drug-induced
liver injury, by defining the constitutive Nrf2-regulated
hepatic proteome.11 We demonstrated that the expression
of a number of proteins responsible for the detoxification
of acetaminophen and other drugs is markedly decreased in
the livers of Nrf2− /− mice,11 consistent with the enhanced
sensitivity of these animals to the hepatotoxicty provoked by
these compounds.12,13 In an extension to this study, we
recently defined the biological processes that are sensitive to
pharmacological modulation of Nrf2 in the liver by detailing
the hepatic protein pool that is augmented in Nrf2+/+ mice,
but not in Nrf2− /− counterparts, in response to CDDO-Me.14
This work revealed that CDDO-Me is a highly selective
inducer of Nrf2-regulated proteins in the liver, and identified
six proteins (cytochrome P450 2A5, glutathione-S-trans-
ferases Mu 1 and Mu 3, ectonucleoside-triphosphate diphos-
phohydrolase, UDP-glucose-6-dehydrogenase, and epoxide
hydrolase) that were both downregulated in Nrf2− /− mice
and upregulated by CDDO-Me in Nrf2+/+ mice.14
In keeping with the role of Nrf2 as a key regulator of cell
defence processes, it is known that Nrf2 protects against a
number of nephrotoxic insults in experimental models, as we
recently reviewed.15 For example, ischemic–reperfusion of the
mouse kidney has been shown to stimulate Nrf2 signaling,16
while the associated renal injury is exacerbated in Nrf2− /−
mice17 and lessened in wild-type mice pretreated with small
molecule Nrf2 inducers.18,19 Similar consequences of Nrf2
inhibition and induction have been noted in the context of
cisplatin-induced proximal tubular cell damage.3 Despite
these and other studies supporting a role for Nrf2 in
protection against acute kidney injury,15 a global analysis of
the biological processes that are regulated by Nrf2 in the
kidney in vivo has yet to be performed. To address this
knowledge gap, we have performed integrated transcriptomic
and proteomic analyses of kidney homogenates from Nrf2+/+
and Nrf2− /− mice, treated or not treated with CDDO-Me.
Our findings support a role for Nrf2 in regulating the
expression of a battery of genes/proteins that contribute to the
maintenance of renal homeostasis.
RESULTS
Genetic and pharmacological modulation of Nrf2 in the
kidney
We first confirmed that CDDO-Me is an effective inducer of
Nrf2 signaling in renal cells, through immunoblot and qPCR
analysis of primary human proximal tubule epithelial cells
following exposure to the compound, which provoked the
accumulation of Nrf2 and upregulated the expression of the
established Nrf2 target NAD(P)H dehydrogenase quinone 1
(Nqo1) at both protein and mRNA levels (Supplementary
Figure S1 online). Nqo1 was also found to be expressed at a
lower level following siRNA depletion of Nrf2, and at a higher
level following transfection with Keap1 siRNA (Supple-
mentary Figure S1 online), confirming that it is a robust
marker of Nrf2 activity in renal cells. In the light of these
findings, we verified that the Nrf2 pathway could be
pharmacologically modulated in the kidneys of Nrf2+/+ mice
and was non-functional in Nrf2− /− mice, before conducting
transcriptomic and proteomic analyses, by determining the
expression level of Nqo1 in kidney homogenates from both
genotypes, 24 h after dosing with vehicle or CDDO-Me.20
The level of Nqo1 protein (Figure 1a and b) and mRNA
(Figure 1c) was significantly lower in the kidneys of vehicle-
exposed Nrf2− /− mice, compared with those of Nrf2+/+
counterparts, consistent with loss of Nrf2 function. Moreover,
while the Nrf2 inducer CDDO-Me provoked the induction
of Nqo1 24 h after administration to Nrf2+/+ mice, this effect
was abrogated in Nrf2− /− mice (Figure 1a–c). Consistent
with these findings, and the established role of Nrf2 in the
protection of mice against pathological insults that target the
cortical tubules,15 there was a significant decrease in Nqo1
immunohistochemical staining in the renal cortex, and
particularly within the proximal tubules, of Nrf2− /− mice,
compared with those of Nrf2+/+ counterparts (Figure 1d
and e). Furthermore, a significant increase in Nqo1 staining
was observed in these structures in Nrf2+/+, but not in
Nrf2− /−, mice in response to CDDO-Me (Figure 1d and e).
Taken together, these data validate our model of genetic and
pharmacological modulation of renal Nrf2 activity, and
provide a platform for a global analysis of the regulatory
roles of Nrf2 in the kidney.
Definition of the Nrf2-regulated renal transcriptome
To characterize the regulatory roles of Nrf2 in the kidney, we
performed microarray analyses on tissue homogenates from
Nrf2+/+ and Nrf2− /− mice treated with vehicle or CDDO-Me
for 24 h (Figure 2a). Of the 27,037 probes recognized in
all samples (Supplementary Table S1 online), 2561 (raw
P⩽ 0.05) or 81 (adj. P⩽ 0.05) probes were differentially
expressed in the kidneys of Nrf2− /− mice, compared with
those of Nrf2+/+ counterparts (Figure 2b, Supplementary
Table S2 online), while 3122 (raw P⩽ 0.05) or 90 (adj.
P⩽ 0.05) probes were differentially expressed in the kidneys
of Nrf2+/+ mice treated with CDDO-Me, compared with
those of vehicle control (Figure 2c, Supplementary Table S3
online). None of the probes that were significantly altered
(adj. P⩽ 0.05) in Nrf2+/+ mice treated with CDDO-Me were
altered in Nrf2− /− mice treated with the compound (Supple-
mentary Table S3 online), demonstrating its relative specifi-
city as an inducer of Nrf2. In keeping with this, ingenuity
pathway analysis (IPA) of the genes that were significantly
downregulated in the kidneys of Nrf2− /− mice, or signifi-
cantly upregulated in the kidneys of Nrf2+/+ mice treated with
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CDDO-Me, demonstrated that the ‘NRF2-mediated Oxidative-
stress Response’ was the most significantly altered pathway in
both cases (Supplementary Table S4 online), supporting the
genetic and pharmacological modulation of Nrf2 in our mouse
model. Nine other pathways, including ‘xenobiotic metabolism
signaling’, ‘aryl hydrocarbon receptor signaling’, ‘PXR/RXR
activation’, and ‘glutathione-mediated detoxification’, were
commonly affected by both genetic inhibition and pharmaco-
logical induction of Nrf2 (Supplementary Table S4 online),
highlighting the role of Nrf2 in regulating homeostatic signaling
processes in the mouse kidney. Only two pathways were
significantly upregulated in the kidneys of Nrf2− /−mice, ‘VDR/
RXR activation’ and ‘β-adrenergic signaling’ (Supplementary
Table S4 online), while none were significantly downregulated
in the kidneys of Nrf2+/+ mice treated with CDDO-Me.
The 64 probes that were significantly downregulated (adj.
P⩽ 0.05) in the kidneys of Nrf2− /− mice represented 56
unique coding genes, while the 65 probes that were
significantly upregulated (adj. P⩽ 0.05) in the kidneys of
Nrf2+/+ mice treated with CDDO-Me represented 57 unique
coding genes. We confirmed the altered expression level of
selected coding genes in the kidneys of Nrf2− /− mice and
CDDO-Me-treated Nrf2+/+ mice by qPCR (Figure 3). Given
that seven genes encoding for transporters were found to be
differentially expressed (adj. P⩽ 0.05) in the kidneys of
Nrf2− /− mice and/or CDDO-Me-treated Nrf2+/+ mice, we
included solute carrier family 38 member 3 (Slc38a3) and
Slc22a12 in this targeted analysis, which confirmed their
lower expression in the kidneys of Nrf2− /− mice (Figure 3a).
Cross-referencing of the microarray data sets revealed that no
probes were both upregulated in Nrf2− /− mice and down-
regulated in CDDO-Me -treated Nrf2+/+ mice, while 12
unique coding genes were found to be both downregulated in
Nrf2− /− mice and upregulated in CDDO-Me-treated Nrf2+/+
mice (Figure 2a, Table 1 and Supplementary Table S5 online).
The differential expression of a subset of these 12 coding
genes was verified by qPCR (Figure 4), which showed good
agreement with the microarray data. It is plausible that
alterations of Nrf2 signaling in other tissues could indirectly
affect the expression of the above genes in the kidneys of
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Figure 1 |Genetic and pharmacological modulation of Nrf2 in the mouse kidney. Mice of the indicated genotype were given a single
intraperitoneal injection of vehicle (DMSO) or CDDO-Me (3 mg/kg) and, 24 h later, Nqo1 levels were determined by (a and b) immunoblotting,
(c) qPCR, and (d and e) immunohistochemical analysis of whole-kidney tissue. (b) Nqo1 band intensities were quantified by densitometry and
normalized against those of β-actin. (c) Nqo1 mRNA levels were normalized to those of Ppia. (d and e) Nqo1 expression levels in the cortex of
Nrf2+/+ mice treated with (i) DMSO or (ii) CDDO-Me, or Nrf2− /− mice treated with (iii) DMSO or (iv) CDDO-Me. G, glomerulus; PT, proximal tubule.
Scale bars represent 50 μm. Data represent mean+s.d. of n=3 (a–c) or n=5 (d and e) animals per group. Statistical analysis was performed with
an unpaired t-test; *P⩽ 0.05; **P⩽ 0.01; ***P⩽ 0.001; NS, nonsignificant. CDDO-Me, methyl-2-cyano-3,12-dioxooleano-1,9-dien-28-oate; DMSO,
dimethyl sulfoxide; qPCR, quantitative polymerase chain reaction.
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Figure 3 |Genes sensitive to genetic inhibition or pharmacological induction of Nrf2 in the mouse kidney. qPCR validation of genes that
were shown to be (a) significantly downregulated in the kidneys of Nrf2− /− mice or (b) significantly upregulated in the kidneys of Nrf2+/+
mice treated with CDDO-Me. Gene expression levels are normalized to those of Ppia. Data represent mean+s.d. of n= 5 animals per group.
Statistical analysis of qPCR data was performed with an unpaired t-test or Mann–Whitney test; *P⩽ 0.05; **P⩽ 0.01; ***P⩽ 0.001;
NS, nonsignificant. CDDO-Me, methyl-2-cyano-3,12-dioxooleano-1,9-dien-28-oate; qPCR, quantitative polymerase chain reaction.
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Figure 2 |Definition of the Nrf2-regulated renal transcriptome. Microarray analysis was performed on kidney tissue from Nrf2+/+ or
Nrf2− /− mice treated with vehicle (DMSO) or CDDO-Me for 24 h. (a) Overview of microarray analysis. DE, differentially expressed. The relevant
supplementary tables are indicated in the boxes. (b and c) Volcano plots depicting differentially expressed genes in the kidneys of (b) Nrf2− /−
mice, compared with those of Nrf2+/+ counterparts, and (c) Nrf2+/+ mice treated with CDDO-Me, compared with those of vehicle. Each point
represents a single gene probe, with those shaded orange (raw P-value) and red (adjusted P-value) found to be significantly different between
groups. CDDO-ME, methyl-2-cyano-3,12-dioxooleano-1,9-dien-28-oate; DMSO, dimethyl sulfoxide.
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Nrf2− /− mice or CDDO-Me-treated Nrf2+/+ mice. However,
bioinformatic analysis identified ARE-like sequences in
many of the genes that were differentially expressed
following genetic and/or pharmacological modulation of
renal Nrf2 activity (Supplementary Table S6 online), includ-
ing those which have been shown previously, through
integrated ChIP-Seq and qPCR analyses, to be bound
by Nrf2 and/or differentially expressed in Nrf2− /− and
Keap1− /− mouse embryonic fibroblasts (Supplementary
Table S7 online).21 Together, these findings indicate a role
for Nrf2 as a transcriptional regulator of the above genes in
the kidney.
Definition of the Nrf2-regulated renal proteome
To complement our transcriptomic analysis of the kidneys of
Nrf2+/+ and Nrf2− /− mice treated with vehicle or CDDO-Me,
we performed isobaric tags for relative and absolute
quantification (iTRAQ)-based proteomic analyses on the
same tissues (Figure 5a). Of the 2557 proteins quantified in at
least four samples from each group at a false discovery rate of
1% (Supplementary Table S8 online), 240 were differentially
expressed (P⩽ 0.05) in the kidneys of Nrf2− /− mice, com-
pared with those of Nrf2+/+ counterparts (Figure 5b, Supple-
mentary Table S9 online). Three of the most substantially
downregulated proteins in the kidneys of Nrf2− /− mice,
Table 1 |Genes/proteins sensitive to genetic inhibition and pharmacological induction of Nrf2 in the mouse kidney
Microarray iTRAQ
Nrf2− /− vs. Nrf2+/+ CDDO-Me vs. Vehicle
Nrf2− /− vs.
Nrf2+/+
CDDO-Me
vs. Vehicle
Gene symbol David ID RefSeq Ratio Adj. P-value Ratio Adj. P-value Accession Ratio P-value Ratio P-value
Abcc2 451709 NM_013806 0.77 9.43−03 1.46 2.79− 04 Q8VI47 0.79 6.66− 03 1.22 4.76− 03
Aldh1l1 430403 NM_027406 0.72 8.21−03 1.38 9.42− 03 Q8R0Y6 0.33 5.14− 10 1.08 2.12− 01
Cyp2a5 420632 NM_007812 0.27 6.17−05 2.04 2.01− 02 P20852 ND ND ND ND
Dpys 425658 NM_001164466 0.29 8.53−06 1.67 4.28− 02 Q9EQF5 0.66 3.78− 02 1.04 7.75− 01
Gclm 425831 NM_008129 0.76 1.40−03 1.28 2.96− 03 O09172 0.81 2.06− 02 1.05 5.59− 01
Gsta3 423583 NM_001077353 0.27 8.20−06 2.13 2.89− 03 P30115 0.16 8.62− 08 0.90 3.42− 01
Gstm1 443311 NM_010358 0.38 3.81−06 1.90 4.37− 04 P10649 0.09 1.14− 10 1.16 5.82− 02
Nampt 465583 NM_021524 0.70 1.08−02 1.44 1.07− 02 Q99KQ4 0.61 8.19− 03 1.22 1.14− 01
Nqo1 481143 NM_008706 0.29 1.45−04 3.47 1.39− 04 Q64669 0.28 1.66− 07 1.36 1.02− 03
Slc35e3 443078 NM_029875 0.84 3.44−02 1.22 1.96− 02 Q6PGC7 ND ND ND ND
Spatc1 429270 NM_028852 0.63 1.68−02 1.80 2.38− 03 Q148B6 ND ND ND ND
Ugt1a10 446962 NM_201641 0.58 9.04−04 1.45 2.12− 02 Q6ZQM8 0.25 6.18− 05 1.09 5.50− 01
Abbreviations: Adj., adjusted; CDDO-Me, methyl-2-cyano-3,12-dioxooleano-1,9-dien-28-oate; DMSO, dimethyl sulfoxide; iTRAQ, isobaric tags for relative and absolute
quantification.
Microarray and iTRAQ analyses were performed on kidney tissue from Nrf2+/+ or Nrf2− /− mice treated with vehicle (DMSO) or CDDO-Me for 24 h. The 12 genes shown
above were found to be both significantly downregulated in the kidneys of Nrf2− /− mice and significantly upregulated in the kidneys of Nrf2+/+ mice treated with CDDO-
Me. From the iTRAQ analysis, nine of the genes were also shown to be significantly downregulated at the protein level in the kidneys of Nrf2− /− mice. The remaining three
genes were not detected (ND) at the protein level by iTRAQ. These nine genes/proteins are therefore considered to be most sensitive to genetic inhibition and
pharmacological induction of Nrf2 in the mouse kidney.
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Figure 4 |Genes sensitive to both genetic inhibition and pharmacological induction of Nrf2 in the mouse kidney. qPCR validation of
genes that were shown to be both significantly downregulated in the kidneys of Nrf2− /− mice and significantly upregulated in the kidneys of
Nrf2+/+ mice treated with CDDO-Me. Gene expression levels are normalized to those of Ppia. Data represent mean+s.d. of n=5 animals per
group. Statistical analysis of qPCR data was performed with an unpaired t-test or Mann–Whitney test; *P⩽ 0.05; **P⩽ 0.01; ***P⩽ 0.001; NS,
nonsignificant. CDDO-Me, methyl-2-cyano-3,12-dioxooleano-1,9-dien-28-oate; qPCR, quantitative polymerase chain reaction.
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glutathione-S-transferase Mu 1 (Gstm1; 11.5-fold lower in
Nrf2− /− vs. Nrf2+/+ mice), catalase (Cat; 4.3-fold lower), and
ectonucleoside-triphosphate diphosphohydrolase (Entpd5;
2.8-fold lower), were also shown by immunoblotting of tissue
homogenates to be expressed at a lower level in the absence
of Nrf2 (Figure 6), demonstrating the robustness of our
proteomic analysis. We also confirmed that the dimethyl
sulfoxide vehicle had little effect on the expression levels of
Nrf2-regulated proteins by performing an independent
iTRAQ analysis of kidney homogenates from untreated
Nrf2+/+ and Nrf2− /− mice (Supplementary Figure S2 online),
which showed excellent agreement with the primary data
set.
Compared with its effects on gene expression, the acute
effects of a single 24-h exposure to CDDO-Me were less
evident at the protein level, with 68 proteins found to be
differentially expressed (P⩽ 0.05) in the kidneys of Nrf2+/+
mice treated with CDDO-Me, compared with those of vehicle
control (Figure 5c, Supplementary Table S10 online). Indeed,
only ATP-binding cassette subfamily C member 2 (Abcc2),
Entpd5, and Nqo1 were both significantly downregulated in
the kidneys of Nrf2− /− mice and significantly upregulated in
the kidneys of Nrf2+/+ mice treated with CDDO-Me
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Figure 5 |Definition of the Nrf2-regulated renal proteome. iTRAQ analysis was performed on kidney tissue from Nrf2+/+ or Nrf2− /− mice
treated with vehicle (DMSO) or CDDO-Me for 24 h. (a) Overview of iTRAQ findings. DE, differentially expressed. The relevant supplementary
tables are indicated in the boxes. (b and c) Volcano plots depicting differentially expressed proteins in the kidneys of (b) Nrf2− /− mice,
compared with those of Nrf2+/+ counterparts, and (c) Nrf2+/+ mice treated with CDDO-Me, compared with those of vehicle. Each point
represents a single protein, with those shaded red found to be significantly different (raw P-value) between groups. CDDO-Me, methyl-2-cyano-
3,12-dioxooleano-1,9-dien-28-oate; DMSO, DMSO, dimethyl sulfoxide; iTRAQ, isobaric tags for relative and absolute quantification.
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(Supplementary Table S11 online). While the relatively
short timeframe used for this experiment (24 h) may not
have been sufficient to provoke significant changes in
the wider battery of Nrf2-regulated proteins, a targeted
analysis revealed minimal additional changes in the expres-
sion of Nqo1, Gstm1, Cat, and Entpd5 (which were sensitive
to genetic inhibition of Nrf2 in the mouse kidney;
Supplementary Table S8 online) at earlier or later time
points, or at different doses of CDDO-Me (Supplementary
Figure S3 online).
IPA interrogation of the proteins that were significantly
downregulated in the kidneys of Nrf2− /− mice, or signifi-
cantly upregulated in the kidneys of Nrf2+/+ mice treated with
CDDO-Me, again demonstrated that the ‘NRF2-mediated
Oxidative Stress Response’ was one of the most significantly
represented pathways in both cases (Supplementary Table S12
online). Examination of the proteomic data also revealed
that modulation of renal Nrf2 activity was associated
with significant alterations in the expression level of proteins
known to regulate core metabolic processes, including
the pentose phosphate pathway (glucose-6-phosphate 1-
dehydrogenase X, G6pdx; 6-phosphogluconate dehydrogen-
ase decarboxylating, Pgd; transketolase, Tkt), the synthesis
and recycling of amino acids (cysteine sulfinic acid decarbox-
ylase, Csad; cystathionine gamma-lyase, Cth; threonine
synthase-like 2, Thnsl2), and the metabolism of lipids/fatty
acids (acetyl-coenzyme A acetyltransferase 1, Acat1; peroxi-
somal acyl-coenzyme A oxidase 3, Acox3; peroxisomal
multifunctional enzyme type 2, Hsd17b4). These findings
further indicate that Nrf2 regulates the expression of genes/
proteins that coordinate renal homeostatic processes.
Comparison of transcriptomic and proteomic data
There was a good level of agreement between our transcrip-
tomic and proteomic data sets (Figure 7). Indeed, IPA
examination of the data from Nrf2− /− mice identified 12
pathways that were commonly altered at both gene and
protein expression levels (Supplementary Tables S4 and S12
online). In keeping with this, of the 12 coding genes that were
both significantly downregulated (adj. P⩽ 0.05) in the kidneys
of Nrf2− /− mice and upregulated in the kidneys of Nrf2+/+
mice treated with CDDO-Me according to our microarray
analysis, 9 were also found in our proteomic analysis to be
significantly (P⩽ 0.05) downregulated at the protein level in
the kidneys of Nrf2− /− mice, while the remaining three
proteins were not detected (Table 1). These data highlight this
panel of genes/proteins as sensitive markers of Nrf2 activity in
the mouse kidney. Most likely due to their low abundance
in whole-tissue homogenates, only 23 of the 72 transporters
that were detected in our microarray analysis of the mouse
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Figure 7 |Correlation of transcriptomic and proteomic analyses of Nrf2 activity in the mouse kidney. Microarray and iTRAQ analyses were
performed on kidney tissue from Nrf2+/+ or Nrf2− /− mice treated with vehicle (DMSO) or CDDO-Me for 24 h. DE, differentially expressed. The
relevant tables are indicated in the boxes. From the microarray analysis, 12 genes were shown to be both significantly downregulated in the
kidneys of Nrf2− /− mice and significantly upregulated in the kidneys of Nrf2+/+ mice treated with CDDO-Me. From the iTRAQ analysis, nine of
the genes were also shown to be significantly downregulated at the protein level in the kidneys of Nrf2− /− mice (the remaining three genes
were not detected at the protein level by iTRAQ). These nine genes/proteins are therefore considered to be most sensitive to genetic inhibition
and pharmacological induction of Nrf2 in the mouse kidney. CDDO-Me, methyl-2-cyano-3,12-dioxooleano-1,9-dien-28-oate; DMSO, dimethyl
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kidney were also present in the iTRAQ data set (Supple-
mentary Table S13 online). Of the seven transporters that
were differentially expressed (adj. P⩽ 0.05) at the mRNA level
in the kidneys of Nrf2− /− mice and/or CDDO-Me -treated
Nrf2+/+ mice, three were detected in our iTRAQ analysis, with
two of these (Abcc2 and Slc22a12) found to have significantly
altered expression in response to genetic and/or pharmaco-
logical modulation of Nrf2 activity (Supplementary Table S13
online).
Nrf2 regulates the provision of NADPH and glutathione in the
kidney
The transcriptomic and proteomic data sets demonstrated
that genes/proteins that are known to regulate the synthesis
and metabolism of NADPH and glutathione were down-
regulated in the kidneys of Nrf2− /− mice. Consistent with
these observations, the levels of NADPH (Figure 8a) and
glutathione (Figure 8b) were found to be significantly lower in
the kidneys of vehicle-treated Nrf2− /− mice, compared with
those of Nrf2+/+ counterparts. The levels of NADPH and
glutathione were not altered by CDDO-Me in Nrf2+/+ or
Nrf2− /− mice (Figure 8a and b), in keeping with the minimal
effects of CDDO-Me at the protein level at 24 h. Taken
together, these data confirm that Nrf2 contributes to the
provision of NADPH and glutathione, which serve as
important cofactors in a number of homeostatic processes,
in the kidney.
DISCUSSION
Delineating the biological processes that are regulated by Nrf2
in the kidney is critical to understand the mechanisms by
which Nrf2 protects against nephrotoxic insults,22 and to
rationalize the pharmacodynamic effects associated with
therapeutic Nrf2 inducers in the kidney.23 Previous work
has demonstrated the role of Nrf2 in regulating the expression
of selected cytoprotective genes in the kidney in vivo and in
renal cells cultured in vitro.17,24 However, prior to this study, a
global analysis of the biological processes that are regulated
by Nrf2 in the kidney in vivo had not been performed. Using
an integrated transcriptomic and proteomic approach, we
have demonstrated that the kidneys of Nrf2− /− mice are
deficient in the expression of genes/proteins that coordinate
the synthesis and conjugation of glutathione, maintain
cellular redox balance, control the metabolism and disposi-
tion of a wide range of xenobiotics, and regulate the supply of
NADPH and other cellular fuels (Figure 9). Consistent with
these observations, we have also shown that Nrf2 influences
the provision of NADPH and glutathione in the kidney
in vivo. These findings demonstrate the role of Nrf2 in
regulating the expression of genes/proteins that contribute to
the maintenance of renal homeostasis.
As we recently reviewed, genetic and pharmacological
modulation of Nrf2 activity has been shown to alter the
threshold for sensitivity to a number of experimental nephro-
toxins.15 For example, cisplatin-induced renal injury is
exacerbated in Nrf2− /− mice and ameliorated in Nrf2+/+
(but not Nrf2− /−) mice by pretreatment with CDDO-Im, a
structural analog of CDDO-Me.3 The primary structural
targets of cisplatin-induced kidney injury are the cortical
tubules, and especially proximal tubule epithelial cells.25 Our
IHC data demonstrate that Nrf2 activity is relatively high
in the cortical tubules, in keeping with a report in healthy
cynomolgus monkeys in which 28-day administration of
CDDO-Me was shown to upregulate Nqo1 expression
predominantly in these structures.26 Notably, Keap1 is also
reported to be expressed at a much higher level in the human
renal cortex than in the medulla.27 These findings are consis-
tent with the ability of Nrf2 and Nqo1 to directly protect
against cisplatin nephrotoxicity in mice.3,28,29 Although
further work is needed to define the contribution of other
proteins and processes to the nephro-protective effects of
Nrf2 in vivo, it is likely that the decreased expression of the
gene battery reported here, and resulting lowered capacity to
adapt to changes in local redox conditions via the provision of
NADPH and glutathione, at least partly contributes to the
enhanced sensitivity to renal insult associated with down-
regulation of Nrf2 signaling.
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One-third of the proteins that we recently showed to be
sensitive to genetic inhibition or pharmacological induction
of Nrf2 in the mouse liver14 were found here to be similarly
regulated by Nrf2 in the kidney, demonstrating that there is a
degree of overlap in the regulatory roles of Nrf2 across
different tissues. Indeed, consistent with our findings in the
kidney, a recent report demonstrated that Nrf2 influences the
provision of NADPH in the liver.30 However, several proteins
found here to be sensitive to modulation of Nrf2 activity in
the kidney were previously shown to be unaltered in the liver,
and vice versa, under the same experimental conditions.14 We
also noted that some Nrf2-regulated genes were down-
regulated to a greater degree in the kidney, compared with the
liver, of Nrf2− /− mice, and vice versa. For example, Gstm1
protein levels were found to be 11.4- and 4.1-fold lower in the
kidneys and livers, respectively, of Nrf2− /− mice compared
with those of wild-type counterparts.14 Given that our IHC
data indicate that Nrf2 activity is relatively high in the cortical
tubules of the kidney, and that our transcriptomic and
proteomic analyses have been conducted on whole-tissue
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homogenates, it will be important to define the biological
actions of Nrf2 in specific regions and cell types within the
kidney, in order to better understand its roles in renal
physiology and disease.
CKD in patients is characterized by a progressive decline in
renal function, reduced metabolic capacity, and an increased
burden of oxidative stress.36,37 Notably, several animal studies
have provided evidence for a downregulation of the
Nrf2 pathway during the pathogenesis of CKD.22 Indeed,
Vaziri and colleagues have observed a higher burden of
oxidative stress and a lower level of expression of Nrf2 and its
target genes, linked to an increase in the level of Keap1, in
rat models of spontaneous focal glomerulosclerosis,38 surgical
nephrectomy,39 and tubulo-interstitial nephropathy.40
The data reported here show that the Slc38a3 gene, which
codes for the sodium-coupled neutral amino acid transporter
3 (Snat3), is expressed at a dramatically lower level in the
kidneys of Nrf2− /− mice. Under physiological conditions,
renal Snat3 protein expression is low (consistent with the
absence of Slc38a3/Snat3 in our iTRAQ data sets) but is
dramatically increased as part of the adaptive response to
metabolic acidosis.34,35 The dysregulation of Snat3 could
render Nrf2− /− mice unable to adapt efficiently to metabolic
acidosis, which is associated with multiple forms of kidney
disease and causes neurological or cardiovascular complica-
tions in patients. We are currently testing this hypothesis.
CDDO-Me and its analogs have previously been shown to
induce Nrf2 signaling and protect against experimental renal
disease in animal models.3,19,31,32 Here, CDDO-Me augmen-
ted the expression of numerous cytoprotective genes in the
mouse kidney, although the pharmacodynamic impact of a
single acute exposure to the compound was less pronounced
at the protein level, even up to 72 h post administration
(Supplementary Figure S3 online). Consistent with this, the
ability of CDDO-Me and its analogs to protect against
experimental acute kidney injury provoked by ferric
nitrilotriacetate,31 cisplatin,3 aristolochic acid,32 and ischemia
reperfusion19 has only been demonstrated following repeated
daily dosing of the triterpenoids, implying that chronic
stimulation is necessary to provoke meaningful changes in the
expression of Nrf2-regulated proteins in the kidney. As a
result, further work is needed to define the effects of repeated
administration of CDDO-Me on the renal Nrf2-regulated
gene battery. In addition, Yates et al.33 have provided evidence
for the differential induction of Nqo1 mRNA in various
tissues of mice following a single 6 h exposure to CDDO-Me
or its structural analogs. Such a phenomenon could be
influenced by drug disposition, and it will therefore be
important to determine whether intraperitoneal injection (as
used here) and oral administration (as used clinically) of
CDDO-Me and other small molecule inducers provoke
different magnitudes of Nrf2 pathway response in the kidney,
and indeed other organs.
CDDO-Me improves estimated glomerular filtration rate
in both cancer and early-stage CKD patients,8 while structural
analogues enhance estimated glomerular filtration rate41 and
renal function42 in rats. Recent work has shown that selected
Nrf2 target genes are upregulated in the glomeruli of Keap1
hypomorphic knockdown mice.43 However, the direct role of
Nrf2 in the improved estimated glomerular filtration rate
observed in patients and animals receiving CDDO-Me or
related triterpenoids is currently unclear. Our microarray data
reveal that none of the transcripts that are significantly altered
by CDDO-Me in Nrf2+/+ mice are similarly altered in
Nrf2− /− KO mice (see Supplementary Table S3 online),
demonstrating the relative specificity of the compound as an
acute inducer of Nrf2 in the kidney. However, it is possible
that during chronic exposure CDDO-Me alters other renal
signaling pathways, or has indirect effects on kidney function
through stimulation of Nrf2 activity in other organs, such as
the liver. Therefore, further work is needed to understand the
pharmacological mechanisms that underlie the beneficial
effect of CDDO-Me on estimated glomerular filtration rate, in
order to support the development of potent, specific, and safe
Nrf2 inducers that may represent promising candidates for
the treatment of CKD, for which new drugs are urgently
required.
MATERIALS AND METHODS
Animals and dosing
Non-fasted male Nrf2+/+ and Nrf2− /− mice (C57BL/6 background,
generation, and genotyping described previously44,45) of 10–12 weeks
of age were utilized throughout the study, which was conducted
according to the Animals (Scientific Procedures) Act 1986 and
University of Liverpool local guidelines. Mice were housed at
19–23 °C on a 12 h light/dark cycle, and given free access to food and
water. Mice were administered a single intraperitoneal dose of
vehicle (dimethyl sulfoxide, 100 μl/mouse) or CDDO-Me (3 mg/kg),
and killed 24 h later by exposure to a rising concentration of
CO2 followed by cardiac puncture. The renal capsule and fat were
removed from excised kidneys, which were then snap frozen, along
with other organs, and stored at − 80 °C.
Microarray analysis and bioinformatics
RNA was isolated from kidney tissue (n= 5 per group) using the
Direct-Zol RNA MiniPrep kit (Zymo Research, Freiburg, Germany)
including on-column DNAse treatment. RNA concentration was
assessed using a NanoDrop ND 1000 (Thermo Scientific, Reinach,
Switzerland) and RNA integrity was determined using a Bioanalyzer
RNA 6000 Chip (Agilent, La Jolla, CA). DNAse-treated total RNA
(270 ng) was subjected to cDNA target synthesis using the Ambion
WT Expression kit (Life Technologies, Lucerne, Switzerland)
following standard recommendations. Fragmentation and labeling
of amplified cDNA were performed using the WT Terminal Labeling
Kit (Affymetrix, High Wycombe, UK) and a TProfessionnal TRIO
PCR machine (Biometra, Goettingen, Germany). A volume of 85 μl
cocktail (23.4 ng/μl labeled DNA) was loaded on Mouse Gene 2.0 ST
arrays (Affymetrix) and hybridized for 17 h (45 °C, 60 r.p.m.) in a
hybridization oven 645 (Affymetrix). The arrays were washed and
stained on a Fluidics Station 450 (Affymetrix) by using the
Hybridization Wash and Stain kit (Affymetrix) under the
FS450_0002 protocol. The GeneChips were scanned with an
Affymetrix GeneChip Scanner 3000 7G. DAT images and CEL files
of the microarrays were generated using Affymetrix GeneChip
Command Control (version 4.0). CEL files were normalized
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according to the robust microarray analysis method46 and data were
log2-transformed. To select differentially expressed genes, a two-way
analysis of variance model, using method of moments,47 was applied.
The false discovery rate adjusted P-values were computed from raw
P-values as described by Benjamini and Hochberg.48 Probes with
transcript IDs but no associated gene assignment, gene symbol, or
RefSeq were excluded from bioinformatic analysis of the microarray
data. To identify coding genes, probes that represented predicted
genes, pseudogenes, uncharacterized cDNAs, Riken cDNAs, and
those without an identifier were excluded. Cross-referencing to
the iTRAQ data set was facilitated by assignment of a DAVID
identifier (http://david.abcc.ncifcrf.gov/conversion.jsp) to relevant
coding genes.
iTRAQ analysis
Individual whole kidneys (n= 6 per group) were homogenized in
0.5 mol/l triethylammonium bicarbonate/0.1% sodium dodecyl
sulfate and subjected to a 1-h freeze–thaw cycle, followed by 3 ×
10 s bursts of sonication (3 μm amplitude). Samples were centrifuged
(12,000 g, 10 min, 4 °C) and supernatants were retained for iTRAQ
and immunoblot analysis. iTRAQ labeling, mass spectrometry, and
data analysis were performed as described.14 Reported proteins were
detected in at least four of six animals per treatment group.
Differential expression (P⩽ 0.05) was determined using the limma
package within the R programming environment,49 enabling
simultaneous comparisons between multiple treatments using design
and contrast matrices via a linear regression model. Cross-
referencing to the microarray data set was facilitated by assignment
of a DAVID identifier to relevant proteins.
IPA and identification of ARE-like sequences
IPA (www.ingenuity.com) of the microarray and iTRAQ data sets
was performed to reveal biological pathways that were perturbed
under the various conditions. Pathways represented by a single gene/
protein were excluded for robustness. Regulatory Sequence Analysis
Tools (RSAT) software (http://www.rsat.eu/)50 was used to identify
ARE sequences in the 5′-flanking regions upstream of putative
Nrf2-regulated genes. 5′-Flanking sequences (5000 bp upstream of
the start codon) were retrieved directly from the ENSEMBL database
from within the RSAT package. Promoter sequences were then
interrogated for ARE or ARE-like sequences using a string-based
analysis with the subprogram ‘dna search’ available within
RSAT. The search terms used were TMAnnRTGABnnnGCR and
TGABnnnGC (where M=A/C, R=A/G, B=G/C/T, and N= any
nucleotide). Consensus ARE sequences were taken from Hayes
et al.51
qPCR analysis
For relative quantification of selected genes, cDNA generated for
microarray analysis of kidney tissue (n= 5 per group) was analyzed,
using KAPA SYBR FAST qPCR reagent (Kapa Biosystems,
Wilmington, MA) on a Rotor-Gene 3000A qPCR machine (Corbett
Research, Cambridge, UK), and normalized to Ppia. Gene-specific
primers are detailed in Supplementary Table S14 online.
Immunoblotting
Tissue homogenates (20 μg protein, n= 6 per group) were separated
by sodium dodecyl sulfate polyacrylamide gel electrophoresis as
previously described.11 The Nqo1 (ab2346), Gstm (ab53942), Entpd5
(ab92542), Cat (ab16731), and β-actin (ab6276) antibodies were
from Abcam (Cambridge, UK). Immunoreactive band volumes were
quantified using TotalLab 100 software (Nonlinear Dynamics,
Newcastle upon Tyne, UK) and normalized to β-actin, which was
probed as a loading control.
Quantification of NADPH and glutathione
Whole-kidney tissue from Nrf2+/+ or Nrf2− /− mice dosed with
dimethyl sulfoxide or CDDO-Me (n= 6 per group) was homo-
genized, and NADPH or glutathione levels were determined using
NADP/NADPH-Glo or GSH-Glo assay kits (Promega, Southampton,
UK), as per the manufacturer’s instructions, with the exception that
NADPH and GSH were quantified after 5 and 2 min incubations,
respectively, of the homogenates with the relevant detection reagents.
NADPH was normalized to total protein content. Glutathione
content was normalized to tissue weight.
Immunohistochemistry and image analysis
Whole kidneys from Nrf2+/+ or Nrf2− /− mice dosed with dimethyl
sulfoxide or CDDO-Me (n= 5 per group) were fixed in 10% neutral
buffered formalin, then longitudinally trimmed and embedded in
paraffin. Serial 4-μm-thick sections were cut and placed on
polylysine-coated slides, rehydrated through serial passages in
solutions at a decreasing concentration of alcohol and moved to
Tris-buffered saline Tween solution, before quenching endogenous
peroxidase activity through incubation in 0.3% hydrogen peroxide.
After blocking non-specific labeling using a 30-min incubation at
room temperature with 20% normal goat serum, the rabbit
polyclonal anti-Nqo1 antibody (HPA007308, Sigma-Aldrich) was
diluted 1:100 in Tris-buffered saline Tween and applied overnight at
4 °C. Negative control staining was performed by replacing the
primary antibody with normal rabbit serum (X0902, Dako, Ely, UK;
see Supplementary Figure S4 online) or by omitting the primary
antibody. Finally, after washing in Tris-buffered saline Tween, anti-
rabbit HRP EnVisionTM polymer detection system (K4011, Dako)
was applied for 30 min at room temperature. After 30 min
incubation with appropriate secondary antibodies, slides were washed
with Tris-buffered saline Tween and 3,3'-diaminobenzidine was added
as chromogen for 10min. Slides were counterstained with Papanicolaou
hematoxylin and mounted. For each experimental animal, a maximum
of 10 non-overlapping microscopic fields of the cortex, including at least
a glomerulus, were captured at ×100 with a Nikon DS-5Mc camera
mounted on a Nikon Eclipse 80i microscope, before automated
processing with ImageJ software. After elaboration of an appropriate
plugin for batch measure, color channel splitting, application of color
threshold, and measurement of the percentage of moderately to strongly
stained areas within the microscopic fields was consecutively and
automatically performed for all images and all experimental groups.
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(2010).
Table S8. iTRAQ data for 2557 proteins quantified in at least four of
six mice from each group.
Table S9. iTRAQ data for 240 proteins found to be differentially
expressed (raw P⩽ 0.05) in the kidneys of Nrf2− /− mice.
Table S10. iTRAQ data for 68 proteins found to be differentially
expressed (raw P⩽ 0.05) in the kidneys of Nrf2+/+ mice treated with
CDDO-Me.
Table S11. iTRAQ data for three proteins found to be both
downregulated (raw P⩽ 0.05) in the kidneys of Nrf2− /− mice and
upregulated (raw P⩽ 0.05) in the kidneys of Nrf2+/+ mice treated with
CDDO-Me.
Table S12. Ingenuity pathway analysis of differentially expressed
proteins in the kidneys of Nrf2− /− mice or Nrf2+/+ mice treated with
CDDO-Me, based on iTRAQ data.
Table S13. Microarray and iTRAQ data for transporter genes and
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http://www.nature.com/ki
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